Last reviewed · How we verify

AZTherapies, Inc. — Portfolio Competitive Intelligence Brief

AZTherapies, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ALZT-OP1b ALZT-OP1b phase 3 Small molecule disease-modifying agent Neurology
ALZT-OP1a ALZT-OP1a phase 3 Multi-target small molecule Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for AZTherapies, Inc.:

Cite this brief

Drug Landscape (2026). AZTherapies, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aztherapies-inc. Accessed 2026-05-16.

Related